Together, Mounjaro and Zepbound brought in $11.98 billion in the third quarter even with price decreases for the medicines.

With a 100% response rate in a Phase II study, KYV-101 sets a new efficacy bar in generalized myasthenia gravis, according to ...

The investment, which will expand Eli Lilly’s existing campus in Puerto Rico, is slated to create 100 new jobs, on top of ...

In this episode presented by PII, BioSpace’s head of insights discusses how China, historically focused on manufacturing, is ...

The Danish pharma was rumored to be a bidder in the process to acquire Metsera earlier this year, which Pfizer ultimately won ...

The FDA has officially placed two of Intellia’s Phase III studies under clinical hold after the biotech reported earlier this ...

Looking for a biopharma job in New York? Check out the BioSpace list of eight companies hiring life sciences professionals ...

Nearly one-third of biotech and pharma professionals are thinking about leaving the U.S. to find biopharma jobs, according to ...

Generic versions of biologic drugs could hit the market without human trials and allow the market forces to bring down costs, ...

Genentech is letting go of 118 employees in San Francisco. The news comes about two months after the biotech ended a ...

Late-breaking Phase III data show ianalumab, Novartis’ dual-targeted antibody, reduced disease activity and patient burden in ...

Eli Lilly and Johnson & Johnson are joining fellow Big Pharma peers in upping their investment in AI, with Lilly looking to ...